# Combine Will Industry blowing hard. Perfect dose.



Bloomberg | Reuters | POEMS COMW: SP | CWIHX.SI | CBWC.SG Industry: Manufacturing (Mechanical Engineering)

Phillip Securities Research Pte Ltd

Buy

Buy

1.340

1.350

0.690

7 March 2012

# Report type: Result & Review

#### **Company Overview**

China-based COMBINE WILL has 3 businesses. ODM/OEM in premiums, household products & toys. Major customers are world-top players in fast-food, FMCG, and toys. Major supplier of plastic-injection and die-cast moulds. Distributes machines used to make these moulds and others.

- Price declined on 4Q result; and, no dividend.
- Profitable 4Q, as guided. But, barely profitable.
- 2012 guidance Imperfect dose of a profitable OEM/ ODM; slow Mould/Tooling; less Machine Sales.
- RIM values it at \$2.69 but fundamental-related price setting gives a more conservative target.
- Maintain BUY with target price of \$1.34.

#### What is the news?

A profitable 4Q11, as guided by management, has been delivered. The profit was small. There would not be any dividend payment – breaking the trend since IPO in June 2008. Management also released an outlook statement a day after the result.

- ODM/OEM: 4Q revenue +1.6% y-y; GP% -3.3pps y-y but +1.6pps q-3Q, +2.3pps q-2Q. Believes it could gain market share as OEM "optimizes supplier base".
- Mould/Tooling: 4Q revenue -19.6% y-y; GP% -12.6pps y-y, -5.1pps q-q. Slower demand, more competition. Economy dependent.
- Machine Sales: 4Q revenue +48.5% y-y; GP% -19.2pps y-y, -5.9pps q-q. Expects FY12 revenue "moderated" vs FY11.

#### How do we view this?

Although we are bullish about its ODM/OEM customers, there are 2 issues at hand. HK\$52m capex spent in FY11 was on machinery and equipment for better automation, which may substitute expensive labour to an extent but may not enhance its capacity or take advantage of cheaper inland labour. Its current share price of under S\$1, as compared to its net debt per share of S\$1.513, would make banks uneasy to offer cheap credit.

Without Korean IPO or banks vulture-ing about, alternative corporate finance could find this easy meat. The plus factors are: Industry is blowing hard; OEM optimizing supplier base; the FMCGs are doing well and guided strongly; CW offers the perfect dose of engineering/design/quality/deliverability/price (children love its toys; adults love its auto-dispensers).

#### **Investment Actions?**

On general market cycle and price/book, this remains a BUY, with target price of \$1.34.

COMBINE WILL
Rating
- Previous Rating
Target Price (SGD)
- Previous Target Price (SGD)
Closing Price (SGD)
Expected Capital Gains (%)
Expected Dividend Yield (%)

COMBINE WILL

Expected Capital Gains (%)	94.2%
Expected Dividend Yield (%)	0.0%
Expected Total Return (%)	94.2%
Raw Beta (POEMS Dataline)	n.a.
Market Cap. (SGD mn)	23
Enterprise Value (SGD mn)	72
3M Average Daily T/O (mn)	0.011
52 week range (SGD)	0.675-3.140



Major Shareholders	(%)
1. DJKS Holdings	73.5

key Financiai Summary				
FYE	12/10	12/11	12/12F	12/13F
Price (*Actual/Current)	2.924	0.690	0.690	0.690
P/B (X)	1.08	0.23	0.22	0.20
EV/EBV (X)	1.03	0.48	0.43	0.47
P/Net Debt (X)	1.94	0.46	0.53	0.35
P/E (X)	5.7	3.3	3.2	2.2
EPS (SGD)	0.514	0.206	0.218	0.319
DPS (SGD)	0.100	0.000	0.000	0.000
Dividend Yield *	3.4%	0.0%	n.a.	n.a.
Source: PSR est.				

\*Actual mean price between publication of FY result and next 1Q result/xDiv

Valuation Method

Koy Einancial Summary

RIM (ROE: 13%; 2 years horizon)

# Analyst

Chan Wai Chee

yebo@phillip.com.sg

+65 6531 1231



#### Segment analysis

We note the decline in margins across the segments. We note that improving productivity may ease the pain. Some OEM suppliers may be blown away and CW may take advantage. However it would really be advantageous if it could expand inland to have the cheaper space and labour costs.

An interesting item in the analysis is the overheads after the gross profit line. The HK\$37m in the ODM/OEM segment for FY11 is actually the lowest of the 4 years although FY11 has the highest revenue. A correlation to the high-ish numbers in FY08 and FY10 is the bid to win major customers i.e. the FMCG customer in FY08 ~ products delivered from FY10; the big toy-maker in FY10 ~ products delivered from FY11.

Fig 1. COMBINE WILL's segmental analysis

Segment Analysis	FY08	FY09	FY10	FY11
Revenue HK\$mn				
- ODM/OEM	778	686	1,129	1,193
- Moulds & Tooling	418	249	269	267
- Machine Sales	149	123	199	318
Total	1,345	1,058	1,597	1,778
Gross Profit HK\$mn				
- ODM/OEM	127	86	161	107
- Moulds & Tooling	61	64	66	48
- Machine Sales	28	17	48	64
Total	216	166	275	220
Gross Profit Margin %				
- ODM/OEM	16.3%	12.5%	14.3%	9.0%
- Moulds & Tooling	14.5%	25.5%	24.5%	18.0%
- Machine Sales	18.7%	13.6%	23.9%	20.2%
Total	<u>16.0</u> %	<u>15.7</u> %	<u>17.2</u> %	<u>12.3</u> %
Overheads HK\$mn				
- ODM/OEM	47	40	58	37
- Moulds & Tooling	40	35	26	33
- Machine Sales	26	16	28	35
Total	113	90	<u>111</u>	105
Overheads Margin %				
- ODM/OEM	6.1%	5.8%	5.1%	3.1%
- Moulds & Tooling	9.5%	13.9%	9.5%	12.3%
- Machine Sales	17.4%	13.0%	14.1%	11.2%
Total	<u>8.4</u> %	<u>8.5</u> %	<u>7.0</u> %	<u>5.9</u> %
EBIT HK\$mn				
- ODM/OEM	80	46	104	70
- Moulds & Tooling	21	29	40	15
- Machine Sales	2	1	19	29
Total	<u>103</u>	<u>76</u>	<u>163</u>	<u>114</u>
Difference	(E)	7.45	(4.4)	(40)
- All segments	(5)	(4)	(11)	(19)
EBIT, as disclosed	<u>97</u>	<u>71</u>	<u>152</u>	<u>95</u>

If there are no major new-customer wins, then the overheads in the ODM/OEM segment may be contained at HK\$40m a year.

#### Other 'hump' items in 4Q11

The high effective tax rate for FY11 is due to non-deductible expenses related to the Korean IPO and the higher profits from the higher-25% tax on China operations. Inventories are high due to January deliveries. Receivables are high due to some customer delivery schedule. Other payable contains some deposit from a Machine Sale customer. Bank loans finance capex.

#### Let's revisit some per-share fundamentals

After hitting \$0.90 since our previous update, the share price slumped back to \$0.69. This translates to 0.23X NBV.

We retain our target price at 0.45X NBV, which was achieved between 2Q09 and 3Q09. This translates back to a share price of **§1.34** (previous target: \$1.35).

Fig 2. COMBINE WILL's quarterly P/B behaviour, overlaid on STI





Fig 3. COMBINE WILL's yearly P/B behaviour, overlaid on STI



#### Valuation, using the Residual Income Method

We apply a ROE of 13% and a 2-year time horizon.

This gives a fair valuation of S\$2.69 (previously \$2.67).

However, due to its low volumes, the Korean IPO hangover, we are using a much more conservative valuation i.e. a P/B valuation similar to the 2Q09 and 3Q09 period.

#### **Target Price**

Our target price of S\$1.34 is 94% higher than the previous close of S\$0.69. Hence, **BUY**.



FYE Dec (Forecasts are based on current price;		IPO: 23	June 2008						
actuals on average prices FY-1Q	result dates)	FY06	FY07	FY08	FY09	FY10	FY11	FY12F	FY13F
Valuation									
P/B		n.a.	0.99	0.25	0.62	1.08	0.23	0.22	0.20
EV/EBV (X) [EBV=Ente	rprise Book Value]	n.a.	0.97	0.34	0.70	1.03	0.48	0.43	0.47
P/ND (X)	[ND=Net Debt]	n.a.	2.0	1.9	1.9	1.9	0.5	0.5	0.3
P/E (X)		n.a.	2.7	1.5	6.3	5.7	3.3	3.2	2.2
DY (%) based on average prices	public-ex dates	n.a.	6.9%	15.7%	6.4%	3.4%	0.0%	n.a.	n.a
Per share data (SGD)									
NBV		1.207	1.462	2.517	2.504	2.706	2.978	3.196	3.515
EBV		1.949	2.240	2.911	3.396	4.295	4.613	4.629	5.674
ND		0.541	0.723	0.338	0.836	1.508	1.513	1.292	1.998
EV		n.a.	2.169	0.975	2.394	4.432	2.203	1.982	2.688
EPS		0.170	0.529	0.439	0.248	0.514	0.206	0.218	0.319
DPS		0.000	0.100	0.100	0.100	0.100	0.000	0.000	0.000
Growth (%)									
NBV per share (same as total)		n.m.	n.m.	72.2%	-0.5%	8.1%	10.0%	7.3%	10.0%
EBV per share (same as total)		n.m.	n.m.	30.0%	16.7%	26.5%	7.4%	0.3%	22.6%
ND per share (same as total)		n.m.	n.m.	-53.3%	147.4%	80.4%	0.3%	-14.6%	54.6%
Revenue		-6.3%	23.2%	10.7%	-21.3%	50.9%	11.3%	1.8%	8.5%
Net Income (same as EPS)		n.m.	210.6%	-17.1%	-43.5%	107.2%	-59.9%	5.8%	46.2%
Return & Margin (%)									
EBI/EBV		13.6%	23.4%	18.0%	9.4%	14.9%	7.8%	7.2%	7.9%
EBI/EBV (standard deviation, 5 ye	ears)	n.a.	n.a.	n.a.	6.9%	5.2%	6.4%	4.8%	3.1%
ROE		n.m.	n.m.	17.4%	9.9%	19.0%	6.9%	6.8%	9.1%
Net Income/Revenue		2.9%	8.2%	5.5%	4.3%	6.5%	2.3%	2.4%	3.2%
Income Statement (HKD mn)									
Revenue		986	1,215	1,345	1,058	1,597	1,778	1,810	1,963
EBIT		49	111	97	71	152	86	74	101
Taxation (net of attributable to fina	ance)	(5)	(13)	(9)	(13)	(23)	(15)	(9)	(13)
EBI		45	98	88	59	130	71	65	88
Net Finance (Expense)/Income		(9)	(10)	(12)	(10)	(16)	(17)	(16)	(18)
Taxation (attributable to finance)		(1)	(1)	(2)	(3)	(3)	(4)	(3)	(4)
Profit After Tax		35	87	74	46	110	50	47	67
Less: Non-controlling Interest		6	(12)	1	1	6	10	4	4
Net Income		29	99	74	45	104	41	43	63
	Effective tax rate %	13.8%	13.8%	12.8%	25.0%	19.1%	24.0%	20.0%	20.0%



FYE Dec	FVoc	EV07	EVOC	EVOO	EV40	FV44	EV40E	EV42E
Balance Sheet (HKD mn) PPE	<b>FY06</b> 228	<b>FY07</b> 217	<b>FY08</b> 237	<b>FY09</b> 242	<b>FY10</b> 295	FY11 304	<b>FY12F</b> 277	<b>FY13F</b> 383
	0		237	242	295		2//	
Land rights & Intangibles Others	0	2 0	0	0	0	2 0	0	2
	228	21 <b>9</b>	<b>239</b>	<b>244</b>	2 <b>97</b>	<b>306</b>	27 <b>9</b>	386
Total non-current enterprise assets (1) Inventories	2 <b>26</b> 185	269	2 <b>39</b> 266	<b>244</b> 276	<b>412</b>	443	460	539
Accounts Receivables	158	190	129	256	317	378	403	463
		84						
Other Receivables	47 <b>390</b>	543	82 <b>477</b>	81 <b>613</b>	173 <b>903</b>	180	196 <b>1,059</b>	203
Total current enterprise assets (2) Total Enterprise Assets (3)=(1)+(2)	618	762	716	857	1,200	1,001 1,307	1,338	1,205 1,590
Accounts Payables	125	150	105	126	1,200	1,307	214	234
•	157	180	105	100	136	197	214	234
Other Payables Others	5	9	15	6	17	7		3
Total current enterprise liabilities (4)	2 <b>86</b>	<b>339</b>	224	232	325	396	(4) <b>424</b>	471
Others	3	3	3	3	3	3	3	3
	3 3	3	3	3	3	3	3	3
Total non-current enterprise liabilities (5)	289	342	228	235	328	399	427	474
Total Enterprise Liabilities (6)=(4)+(5)								
Enterprise Book Value (7)=(3)-(6)	328	420	489	622	872	908	911	1,117
Short-term loans	133	209	162	332	566	541	495	635
Current portion of long-term loans	0	0	0	0	35	53	53	53
Total current financial liabilities (8)	133	209	162	332	601	595	548	688
Non-current portion of long-term loans	11	0	0	0	94	141	141	141
Total non-current financial liabilities (9)	11	0	0	0	94	141	141	141
Total Financial Liabilities (10)=(8)+(9)	144	209	162	332	695	736	689	829
Cash and bank	53	74	106	179	160	109	105	106
Pledged deposits	0	0	0	0	229	330	330	330
Total current financial assets (11)	53	74	106	179	389	438	435	436
Others	0	0	0	0	0	0	0	0
Total non-current financial assets (12)	0	0	0	0	0	0	0	0
Total Financial Assets (13)=(11)+(12)	53	74	106	179	389	438	435	436
Net Debt (14)=(10)-(13)	91	136	57	153	306	298	254	393
Non-controlling interest	34	10	9	10	16	24	28	32
Shareholder Equity	203	274	422	458	550	586	629	692
Total Equity (15)	237	284	432	469	566	610	657	723
Financing Activities (16)=(14)+(15)	328	420	489	622	872	908	911	1,117
Cashflow Statements (HKD mn)								
CFO								
PBT	43	101	84	61	136	69	58	83
Adjustments	47	26	62	59	69	71	68	64
Cash from ops before WC ex-financials' changes	89	127	146	120	205	139	126	147
WC ex-financials' changes	(22)	(89)	(38)	(114)	(205)	(10)	(19)	(106)
Cash generated from operations	68	38	108	6	0	130	107	41
Taxes paid, net of attributable finance	(3)	(9)	(3)	(21)	(12)	(33)	(19)	(6)
Cashflow from Operations (17)	64	30	105	(15)	(12)	97	87	35
CFI								
PPE, land rights, intangibles net	(38)	(28)	(66)	(51)	(103)	(52)	(25)	(153)
Cashflow from Investments (18)	(38)	(28)	(66)	(51)	(103)	(52)	(25)	(153)
Cshflow from Enterprise (19)=(17)+(18)	26	2	39	(67)	(115)	45	62	(117)
CFF								
Share issuance	0	0	104	0	0	0	0	0
Purchase of treasury shares	0	0	0	0	0	0	0	0
Loans, net of repayments	(1)	65	(43)	170	363	39	(47)	140
Pledged deposits	0	0	0	0	(229)	(101)	0	0
Issue of term note, net	0	0	0	0	0	0	0	0
Dividends to minority interests	(2)	(1)	(2)	0	0	(2)	0	0
Dividends to shareholders & capital reduction	(25)	(34)	(53)	(17)	(19)	(21)	(0)	0
Finance expense, net of income	(4)	(10)	(12)	(10)	(16)	(17)	(16)	(18)
Taxes paid, attributable finance	(1)	(1)	(2)	(3)	(3)	(4)	(3)	(4)
Cashflow from Financing (20)	(33)	19	(7)	140	96	(106)	(66)	118
Net change in Cash (21)=(19)+(20)	(7)	21	32	73	(19)	(60)	(3)	1
Effects of exchange rates	0	0	0	0	0	9	0	0
								405
CCE, begin	60	53	74	106	179	160	109	105

Source: PSR



QE Mar,	Jun, S	Sep,	Dec	(Forecast	on	current	price;
---------	--------	------	-----	-----------	----	---------	--------

actuals on average prices q-q result dates)	4Q10	1Q11	2Q11	3Q11	4Q11	1Q12F	2Q12F	3Q12F	4Q12F
Valuation									
P/B	1.08	0.90	0.33	0.27	0.2317	0.23	0.22	0.22	0.22
EV/EBV (X) [EBV=Enterprise Book Value]	1.03	0.92	0.59	0.54	0.48	0.47	0.45	0.44	0.43
P/ND (X) [ND=Net Debt]	1.9	1.5	0.5	0.4	0.5	0.5	0.5	0.5	0.5
P/E (X) trailing 4qs	5.7	5.1	2.3	2.1	3.3	4.1	4.4	4.1	3.2
DY (%) based on average prices public-ex dates	3.4%	0.0%	0.0%	0.0%	n.a.	n.a.	n.a.	n.a.	n.a.
Per share data (SGD)									
NBV	2.714	2.731	2.764	2.952	2.978	3.017	3.079	3.142	3.196
EBV	4.306	4.453	4.784	4.936	4.613	4.602	4.562	4.634	4.629
ND	1.512	1.629	1.899	1.860	1.513	1.459	1.352	1.355	1.292
EV	4.454	4.090	2.819	2.666	2.203	2.149	2.042	2.045	1.982
EPS	0.172	0.074	0.070	0.051	0.004	0.039	0.062	0.063	0.054
DPS	0.100	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Growth (%q-q)									
NBV per share (same as total)	4.4%	0.7%	1.2%	6.8%	0.9%	1.3%	2.1%	2.1%	1.7%
EBV per share (same as total)	2.1%	3.4%	7.4%	3.2%	-6.5%	-0.2%	-0.9%	1.6%	-0.1%
ND per share (same as total)	-2.4%	7.7%	16.6%	-2.1%	-18.6%	-3.6%	-7.3%	0.3%	-4.7%
Revenue	22.7%	5.2%	3.0%	-11.6%	7.6%	1.3%	-1.1%	2.2%	1.0%
Net Income (same as EPS)	86.2%	-56.8%	-5.7%	-27.6%	-92.6%	934.8%	59.4%	1.9%	-15.1%
Return & Margin (%)									
EBI/EBV	5.0%	2.6%	2.5%	1.5%	1.1%	1.5%	2.0%	2.0%	1.7%
EBI/EBV (standard deviation, 5qs)	n.a.	1.3%	1.5%	1.3%	1.5%	0.7%	0.5%	0.4%	0.4%
ROE	6.3%	2.7%	2.5%	1.7%	0.1%	1.3%	2.0%	2.0%	1.7%
Net Income/Revenue	8.1%	3.4%	3.1%	2.4%	0.2%	1.7%	2.7%	2.7%	2.3%
Income Statement (HKD mn)									
Revenue	431	454	467	413	444	450	445	455	460
EBIT	52	28	28	17	12	15	20	21	18
Taxation (net of attributable to finance)	(8)	(4)	(4)	(2)	(3)	(1)	(3)	(3)	(2)
EBI	44	24	24	15	10	14	18	18	16
Net Finance (Expense)/Income	(5)	(5)	(4)	(4)	(4)	(4)	(4)	(4)	(4)
Taxation (attributable to finance)	(1)	(1)	(1)	(1)	(3)	(1)	(1)	(1)	(1)
Profit After Tax	38	19	19	10	2	9	13	13	11
Less: Non-controlling Interest	3	3	5	0	1	1	1	1	1
Net Income	35	15	14	10	1	8	12	12	11
		.0			•		12	14	



Balance Sheet (HKD mn)	4Q10	1Q11	2Q11	3Q11	4Q11	1Q12F	2Q12F	3Q12F	4Q12I
PPE	295	286	303	295	304	296	288	280	277
Land rights & Intangibles	2	2	2	2	2	2	2	2	2
Others	0	0	0	0	0	0	0	0	0
Total non-current enterprise assets (1)	297	288	306	297	306	298	290	282	279
Inventories	412	475	512	493	443	450	445	455	460
Accounts Receivables	317	311	352	412	378	394	393	398	403
Other Receivables	173	198	201	183	180	184	188	192 1 045	196
Total current enterprise assets (2)	903	983	1,065	1,088	1,001	1,028	1,026	1,045	1,059
Total Enterprise Assets (3)=(1)+(2)	1,200	1,271	1,371	1,385	1,307	1,326	1,316	1,327	1,338
Accounts Payables	172 136	166	180	191	197 193	209 209	212 212	209 209	214 214
Other Payables	130	161	195	196	7				
Others	325	14 <b>341</b>	18 <b>393</b>	23 <b>410</b>	396	(1) <b>417</b>	(8) <b>415</b>	(6) <b>412</b>	(4 <b>424</b>
Total current enterprise liabilities (4) Others	3	341	3	3	3	3	3	3	3
Total non-current enterprise liabilities (5)	3 3	3	3	3	3	3	3	3	3
Total Enterprise Liabilities (6)=(4)+(5)	328	344	396	413	399	420	418	415	427
Enterprise Book Value (7)=(3)-(6)	872	927	975	972	908	906	898	912	911
Enterprise Book value (1)=(3)-(0)	0/2	321	313	312	300	300	030	312	311
Short-term loans	566	699	930	927	541	525	505	505	495
Current portion of long-term loans	35	35	30	34	53	53	53	53	53
Total current financial liabilities (8)	601	734	961	960	595	578	558	558	548
Non-current portion of long-term loans	94	86	81	113	141	141	141	141	141
Total non-current financial liabilities (9)	94	86	81	113	141	141	141	141	141
Total Financial Liabilities (10)=(8)+(9)	695	820	1,042	1,073	736	719	699	699	689
Cash and bank	160	117	96	136	109	103	104	103	105
Pledged deposits	229	364	559	572	330	330	330	330	330
Total current financial assets (11)	389	481	655	707	438	432	433	433	435
Others	0	0	0	0	0	0	0	0	C
Total non-current financial assets (12)	0	0	0	0	0	0	0	0	0
Total Financial Assets (13)=(11)+(12)	389	481	655	707	438	432	433	433	435
Net Debt (14)=(10)-(13)	306	339	387	366	298	287	266	267	254
Non-controlling interest	16	19	25	25	24	25	26	27	28
Shareholder Equity	550	569	563	581	586	594	606	618	629
Total Equity (15)	566	588	588	606	610	619	632	645	657
Financing Activities (16)=(14)+(15)	872	927	975	972	908	906	898	912	911
Cashflow Statements (HKD mn)									
CFO	40	0.4	0.4	40		44	40	47	4.4
PBT	46	24	24	13	8	11	16	17	14
Adjustments	19	18	17	16	19	17	17	17	17
Cash from ops before WC ex-financials' changes	65	42	41	30	27	28	33	34	31
WC ex-financials' changes	(52)	(58)	(50)	3	89	2	7	(24)	(4
Cash generated from operations	13	(16)	(8)	33	116	30	41	9	27
Taxes paid, net of attributable finance	(6) <b>8</b>	(7)	(0)	3	(19) <b>97</b>	(9)	(10) <b>31</b>	(1) <b>9</b>	(C <b>27</b>
Cashflow from Operations (17) CFI	0	(24)	(8)	36	91	21	31	9	21
	(3)	(4)	(33)	(4)	(11)	(5)	(5)	(5)	(10
PPE, land rights, intangibles net Cashflow from Investments (18)	, ,	٠,	(33)	(4)	(11) (11)	٠,,		. ,	,
Cashflow from Enterprise (19)=(17)+(18)	(3) 5	(4) (28)	(41)	(4) 33	85	(5) 16	(5) 26	(5) 4	(10 17
CFF	3	(20)	(41)	33	65	10	20	*	17
	0	0	0	0	0	0	0	0	C
Share issuance	0	0	0	0	0	0	0	0	C
Purchase of treasury shares		125	222					0	
Loans, net of repayments	289 (229)	(135)		31 0	(339) 229	(17) 0	(20) 0	0	(10
Pledged deposits Issue of term note, net			(195) 0	0	0	0	0	0	
Dividends to minority interests	0	0	0	0	(2)	(0)	0	0	
Dividends to minority interests  Dividends to shareholders & capital reduction	0	0	(2)	(19)	(2) 0	0	0	0	(0
•	(5)	(5)	(4)		(4)	(4)	(4)		(4
Finance expense, net of income				(4)				(4)	
Taxes paid, attributable finance  Cashflow from Financing (20)	(1) <b>54</b>	(1) <b>(15)</b>	(1) <b>20</b>	(1) <b>7</b>	(3) <b>(119)</b>	(1) <b>(22)</b>	(1) <b>(25)</b>	(1) (4)	(1 (14
- · ·	59	(43)		40			(23)	(4) (1)	(12
Net change in Cash (21)=(19)+(20)  Effects of exchange rates	<b>59</b> 0	( <b>43)</b> 0	<b>(21)</b> 0	<b>40</b> 0	<b>(34)</b> 7	<b>(6)</b> 0	0	<b>(1)</b> 0	(
<u> </u>	101			96		109	103	104	
CCE, begin CCE, end	101 <b>160</b>	160 <b>117</b>	117 <b>96</b>	96 <b>136</b>	136 <b>109</b>	109 <b>103</b>	103 <b>104</b>	104 <b>103</b>	103 <b>105</b>





<b>PSR Rating Syste</b>	m	
Total Returns	Recommendation	Rating
> +20%	Buy	1
+5% to +20%	Accumulate	2
-5% to +5%	Neutral	3
-5% to -20%	Reduce	4
>-20%	Sell	5
_		

#### Remarks

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation



#### **Important Information**

This publication is prepared by Phillip Securities Research Pte Ltd., 250 North Bridge Road, #06-00, Raffles City Tower, Singapore 179101 (Registration Number: 198803136N), which is regulated by the Monetary Authority of Singapore ("Phillip Securities Research"). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below.

This publication has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this document by mistake, please delete or destroy it, and notify the sender immediately. Phillip Securities Research shall not be liable for any direct or consequential loss arising from any use of material contained in this publication.

The information contained in this publication has been obtained from public sources, which Phillip Securities Research has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively, the "Research") contained in this publication are based on such information and are expressions of belief of the individual author or the indicated source (as applicable) only. Phillip Securities Research has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete, appropriate or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the preparation or issuance of this report, (i) be liable in any manner whatsoever for any consequences (including but not limited to any special, direct, incidental or consequential losses, loss of profits and damages) of any reliance or usage of this publication or (ii) accept any legal responsibility from any person who receives this publication, even if it has been advised of the possibility of such damages. You must make the final investment decision and accept all responsibility for your investment decision, including, but not limited to your reliance on the information, data and/or other materials presented in this publication.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice.

Past performance of any product referred to in this publication is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This publication should not be relied upon exclusively or as authoritative, without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this research should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this publication, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the



preparation or issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this publication.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold a interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this publication. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the preparation or issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the preparation or issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this material.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

Section 27 of the Financial Advisers Act (Cap. 110) of Singapore and the MAS Notice on Recommendations on Investment Products (FAA-N01) do not apply in respect of this publication.

This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

Please contact Phillip Securities Research at [65 65311240] in respect of any matters arising from, or in connection with, this document.

This report is only for the purpose of distribution in Singapore.

# **Contact Information (Singapore Research Team)**

#### **Chan Wai Chee**

CEO, Research Special Opportunities +65 6531 1231 yebo@phillip.com.sg

## **Magdalene Choong**

Investment Analyst
SG & US Financials, Gaming
+65 6531 1791
magdalenechoongss@phillip.com.sg

#### Nicholas Low, CFA

Investment Analyst Commodities, Offshore & Marine +65 6531 1535 nicholaslowkc@phillip.com.sg

#### Ken Ang

Investment Analyst
Financials
+65 6531 1793
Kenangwy@phillip.com.sg

#### Lee Kok Joo, CFA

Head of Research S-Chips, Strategy +65 6531 1685 leekj@phillip.com.sg

## Go Choon Koay, Bryan

Investment Analyst
Property
+65 6531 1792
gock@phillip.com.sg

#### **Travis Seah**

Investment Analyst
REITS
+65 6531 1229
travisseahhk@phillip.com.sg

#### Joshua Tan

Strategist +65 6531 1249 joshuatan@phillip.com.sg

#### **Derrick Heng**

Investment Analyst
Transportation, Telecom.
+65 6531 1221
derrickhengch@phillip.com.sg

## **Peter Lee**

Research Assistant General Enquiries +65 6531 1240 (Phone) +65 6336 7607 (Fax) research@phillip.com.sg

#### **Contact Information (Regional Member Companies)**

#### **SINGAPORE**

# **Phillip Securities Pte Ltd**

Raffles City Tower 250, North Bridge Road #06-00 Singapore 179101 Tel: (65) 6533 6001 Fax: (65) 6535 6631

Website: www.poems.com.sg

#### HONG KONG

# Phillip Securities (HK) Ltd

Exchange Participant of the Stock Exchange of Hong Kong 11/F United Centre 95 Queensway Hong Kong Tel (852) 22776600 Fax (852) 28685307

Websites: www.phillip.com.hk

#### **INDONESIA**

# PT Phillip Securities Indonesia

ANZ Tower Level 23B, JI Jend Sudirman Kav 33A Jakarta 10220 – Indonesia Tel (62-21) 57900800 Fax (62-21) 57900809 Website: www.phillip.co.id

#### **THAILAND**

# Phillip Securities (Thailand) Public Co. Ltd

15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel (66-2) 6351700 / 22680999 Fax (66-2) 22680921 Website www.phillip.co.th

# UNITED KINGDOM

#### King & Shaxson Capital Limited

6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel (44-20) 7426 5950 Fax (44-20) 7626 1757

Website: www.kingandshaxson.com

# AUSTRALIA PhillipCapital Australia

Level 37, 530 Collins Street, Melbourne, Victoria 3000, Australia Tel (613) 96298380 Fax (613) 96148309

Website: www.phillipcapital.com.au

#### **MALAYSIA**

# Phillip Capital Management Sdn Bhd

B-3-6 Block B Level 3 Megan Avenue II, No. 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur Tel (603) 21628841 Fax (603) 21665099

Website: www.poems.com.my

#### **JAPAN**

#### PhillipCapital Japan K.K.

Nagata-cho Bldg., 8F, 2-4-3 Nagata-cho, Chiyoda-ku, Tokyo 100-0014 Tel (81-3) 35953631 Fax (81-3) 35953630 Website:www.phillip.co.jp

#### **CHINA**

#### Phillip Financial Advisory (Shanghai) Co. Ltd

No 550 Yan An East Road, Ocean Tower Unit 2318, Postal code 200001 Tel (86-21) 51699200 Fax (86-21) 63512940 Website: www.phillip.com.cn

#### **FRANCE**

## King & Shaxson Capital Limited

3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France Tel (33-1) 45633100 Fax (33-1) 45636017

Website: www.kingandshaxson.com

# **UNITED STATES**Phillip Futures Inc

141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA Tel +1.312.356.9000 Fax +1.312.356.9005

